

IN THE VITED STATES PATENT AND TRADER (NOT USE for PCT Applications) For Design or Utility Applications

(A) (18,00 10) (18,00

Attn: Application Division

	Acti: Application Division
In re <u>PATENT APPLICATION</u> of Inventor(s): STRACKE et al.	(Our Deposit Account No. 03-3975 (Our Order No. 5683 / 92382
Appln. No.: 0 7 / 822,043 series code † / † serial no. Filed: January 17, 1992	C# / M# Atty. Dkt. 92382 / E-142-90 M# / Client Ref.
Title: AUTOTAXIN: MOTILITY STIMULATING PROTEIN USEFUL IN CANCER DIAGNOSIS AND THERAPY Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231	Date: March 17, 1992
Sir:	
In reply to the <u>Notice to File Missing Parts (copy attached 53(d)</u> of the above-identified patent application:), the following <u>completes the filing</u> under <u>Rule</u>
1. [X] Signed Declaration per Rule 53(d) attached.	
 [] Attached: Original signed Declaration with attached a copy of specification and claim(s) originally: 	
3. [] The original application as filed in the PTO on each inventor executed by signing the attached R	
4. [] Specification originally filed in non-English la	nguage; hence verified translation attached of:
a. [] Abstract b. [] pgs. of Specification (only spec. c. [] Drawing Figs	& claims)
5. [] Letter filing formal drawing attached.	
6. [X] Attached is an assignment to <u>UNITED STATES OF AM</u> OF HEALTH AND HUMAN SERVICES	ERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT
Please return the recorded assignment to the und	ersigned.
(1) (4) (2) (5)	d on filing in (country)
8 (No.) Certified copy/copies [] attached; []	previously filed <u>(date)</u>
9. in U.S. Application No., 0 / , fil series code † † serial no.	ed
10. [] Attached:(No.) Statement(s) establishing "sm	
11. [XX] Attached: SUBMISSION, PTO-1449 and references (080 KJ 03/24/92 07822043 080 KJ 03/24/92 07822043	6) 1 101 978.00 CK 1 101 970.00 CK
OBO KJ 03/24/92 07822043	1 105 130.00 CK





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE

FIRST NAMED APPLICANT

ATTY DOCKET NO /TITLE

7822.043

01/17/92

STRACKE

32

AND

CUSHMAN, DARBY & CUSHMAN 1615 L STREET, NW ELEVENTH FLOOR WASHINGFOR, DC 20006 SAUL

(L()H()

DATE MAILED:

01 (31, 92)

NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED

A fil	ing date has been granted to this application. However, the following parts are missing.
If all	missing parts are filed within the period set below, the total amount owed by applicant as a
☐ large entity, ☐ small entity (verified statement filed), is \$ ////)	
1. 🗹	The statutory basic filing fee is: missing insufficient. Applicant as a large entity
	small entity, must submit \$ (1) 1 to complete the basic filing fee and MUST ALSO SUBMIT THE SURCHARGE AS INDICATED BELOW.
2. 🗹	Additional claim fees of \$ as a
3. ☑	The oath or declaration: ☑ is missing. □ does not cover items omitted at time of execution.
	An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required. A SURCHARGE MUST ALSO BE SUBMITTED AS INDICATED BELOW.
4. 🗆	The eath or declaration does not identify the application to which it applies. An eath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required. A SURCHARGE MUST ALSO BE SUBMITTED AS INDICATED BELOW.
5. 🗆	The signature to the oath or declaration is: \square missing; \square a reproduction; \square by a person other than the inventor or a person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required. A SURCHARGE MUST ALSO BE SUBMITTED AS INDICATED BELOW
6. 🗆	The signature of the following joint inventor(s) is missing from the oath or declaration:
	. An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Receipt Date is required. A SURCHARGE MUST ALSO BE SUBMITTED AS INDICATED BELOW.
7. 🗆	The application was filed in a language other than English. Applicant must file a verified English translation of the application and a fee of \$30.00 under 37 CFR 1.17(k), unless this fee has already been paid. NO SURCHARGE IS RERQUIRED FOR THIS ITEM.
8. 🗆	A \$50.00 processing fee is required for returned checks. (37 CFR 1.21(m)).
9. 🗆	Your filing receipt was mailed in error because check was returned without payment.
0. 🗆	Other.
•	An Application Number and Filing Date have been assigned to this application. The missing parts and fees identified above in items 1 and 3-6 must be timely provided ALONG WITH THE PAYMENT OF A SURCHARGE of \$120.00 for large entities or \$60.00 for small entities who have filed a verified statement claiming such status. The surchage is set forth in 37 CFR 1.16(e). Applicant is given ONE MONTH FROM THE DATE OF THIS LETTER, OR TWO MONTHS FROM THE FILING DATE of this application, WHICHEVER IS LATER, within which to file all missing parts and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).
Direct (Special	he response to, and any questions about, this notice to ATTENTION: Application Division, Handling Unit.

A copy of this notice <u>MUST</u> be returned with response.

For: Manager, Application Division (703) 557- 1303

FORM PTO-1533 (REV. 6-90)

COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re PATENT APPLICATION of

STRACKE et al.

Group Art Unit: Unknown

Appln. No. 07/822,043

Examiner: Unknown

Filed: January 17, 1992

Title:

AUTOTAXIN: MOTILITY STIMULATING PROTEIN USEFUL IN CANCER DIAGNOSIS

AND THERAPY

March 17, 1992

SUBMISSION

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Attached hereto for the Examiner's consideration in the examination of this application, are copies of references by the inventors either cited in the present specification and/or believed to be relevant in the examination of the present application. Included also is form PTO-1449 listing these references.

Liotta et al. (Proc. Natl. Acad. Sci. USA, 83: 3302-3306) which describes the original observation that an autocrine motility factor (AMF) was produced in a human melanoma cell line and 1992 Stracke et al. (J. Biol Chem., 267: 2523-2529) describes the purification and partial sequence analysis of autotaxin. Other papers which are enclosed include the 1987 Stracke et al. (Biochem. Biophys. Res. Comm. 146: 339-345) which

STRACKE et al. -- Appln. No. 07/822,043

describes the pertussis toxin sensitivity of the AMF, the 1988 Stracke et al. (Biochem. Biophys. res. Comm., 153: 1076-1083) which describes insulin-like growth factor-1 (IGF-1) as a non-pertussis toxin sensitive motility-stimulating factor in the same cell line, the 1989 Stracke et al. (J. Biol, Chem., 264: 21544-21549) which establishes that the type I IGF receptor is responsible for IGF-I- but not AMF-stimulated motility, and the 1990 Aznavoorian et al. (J. Cell Biol., 110: 1427-1438) which establishes that these same cells locomote in response to extracellular matrix components.

The Examiner is requested to consider the attached in the examination of this application.

Respectfully submitted,
CUSHMAN, DARBY & CUSHMAN

Watson T. Scott

Reg. No. 26,581

Tel. No.: (202) 861-3067 Fax No.: (202) 822-0944

WTS/BJS/par

1615 L Street, N.W. Eleventh Floor Washington, D.C. 20036-5601 (202) 861-3000